Biocaps Biocaps

Immutopics International, based in San Clemente, CA, is a leading provider of innovative methods for assessing bone health. Their diagnostic kits cater to a wide range of species including humans, rats, mice, pigs, cows, and dogs. Specializing in bone health diagnostics, Immutopics Inc offers cutting-edge solutions for researchers and healthcare professionals seeking accurate and reliable assessments. Their expertise spans across multiple species, making them a versatile choice in the field. Generated from their available business information

American Peptide Company offers a vast range of pharmaceutical-grade peptides, as well as products and services for protein research applications. It features Boc/Fmoc amino acid derivatives and resins for custom peptide synthesis. The company s capabilities include peptide-protein conjugation, quantities to kilograms, multiple disulfide bridges, complex peptides, peptidomimetics and specialty amino acids and derivatives. APC s scientists are experienced with phosphorylated and biotinylated structures, chromogenic and fluorogenic substrates, process development and solid-phase, solution and segment coupling technologies. The company s FDA-licensed cGMP facilities are designed for large-scale manufacturing of pharmaceutical drug substances for clinical research. American Peptide Company is a subsidiary of Itoham Foods and is based in Sunnyvale, Calif.

Xencor is a biotechnology company based in Monrovia, California, focused on developing innovative antibody therapeutics, particularly in the realm of bispecific antibodies. Utilizing its proprietary XmAb protein engineering platform, Xencor is advancing a diverse pipeline of drug candidates aimed at treating cancer and other serious diseases, with numerous programs currently in clinical testing. The company's unique approach allows for the creation of highly selective immune-modulators and targeted cancer therapies, enhancing treatment efficacy while improving stability and manufacturability. As an industry leader in bispecific antibodies, Xencor continues to forge partnerships and expand the therapeutic boundaries of antibody drugs. Generated from the website